Candida infections, causes, targets, and resistance mechanisms: Traditional and alternative antifungal agents

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Spampinato, Claudia ^a,b   Leonardi, Darío ^a,c  

^a UNIVERSIDAD NACIONAL DE ROSARIO   (Argentina)

^b Centro de Estudios Fotosinteticos Y Bioquimicos   (Argentina)

^c Universidad Nacional de Rosario   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ALBACONAZOLE; AMOROLFINE; AMPHOTERICIN B; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; CLOTRIMAZOLE; E 1210; ECONAZOLE; FLUCONAZOLE; FLUCYTOSINE; GRISEOFULVIN; IMIDAZOLE; ISAVUCONAZOLE; ISAVUCONAZONIUM; ITRACONAZOLE; KETOCONAZOLE; MICAFUNGIN; MICONAZOLE; NAFTIFINE; NORBORNENE DERIVATIVE; NYSTATIN; POSACONAZOLE; SAPONIN; SERAGIKINONE A; TERBINAFINE; TOLCICLATE; TOLNAFTATE; UNCLASSIFIED DRUG; VORICONAZOLE; XESTODECALACTONE B;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL RESISTANCE; ANTIMICROBIAL THERAPY; AREA UNDER THE CURVE; BINDING AFFINITY; CANDIDIASIS; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG TARGETING; GENETIC RESISTANCE; HUMAN; IN VITRO STUDY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; POINT MUTATION; REVIEW; CANDIDA; MICROBIOLOGY; PATHOGENICITY;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; DRUG RESISTANCE, FUNGAL; HUMANS;

EID: 84880158294     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/204237     Document Type: Review

References (149)

1. Jackson B. E., Wilhelmus K. R., Mitchell B. M., Genetically regulated filamentation contributes to Candida albicans virulence during corneal infection. Microbial Pathogenesis 2007 42 2-3 88 93 2-s2.0-33847146682 10.1016/j.micpath.2006.11.005
2. Wu T. G., Mitchell B. M., Carothers T. S., Coats D. K., Brady-McCreery K. M., Paysse E. A., Wilhelmus K. R., Molecular analysis of the pediatric ocular surface for fungi. Current Eye Research 2003 26 1 33 36 2-s2.0-0042266466 10.1076/ceyr.26.1.33.14253
3. Achkar J. M., Fries B. C., Candida infections of the genitourinary tract. Clinical Microbiology Reviews 2010 23 2 253 273 2-s2.0-77950675511 10.1128/CMR.00076-09
4. Rosenbach A., Dignard D., Pierce J. V., Whiteway M., Kumamoto C. A., Adaptations of Candida albicans for growth in the mammalian intestinal tract. Eukaryotic Cell 2010 9 7 1075 1086 2-s2.0-77956799388 10.1128/EC.00034-10
5. Naglik J. R., Moyes D. L., Wächtler B., Hube B., Candida albicans interactions with epithelial cells and mucosal immunity. Microbes and Infection 2011 13 12-13 963 976 2-s2.0-80053385024 10.1016/j.micinf.2011.06.009
6. López-Martínez R., Candidosis, a new challenge. Clinics in Dermatology 2010 28 178 184 10.1016/j.clindermatol.2009.12.014
7. Kontoyiannis D. P., Mantadakis E., Samonis G., Systemic mycoses in the immunocompromised host: an update in antifungal therapy. Journal of Hospital Infection 2003 53 4 243 258 2-s2.0-0038159878 10.1053/jhin.2002.1278
8. Zaoutis T. E., Argon J., Chu J., Berlin J. A., Walsh T. J., Feudtner C., The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clinical Infectious Diseases 2005 41 9 1232 1239 2-s2.0-27444432361 10.1086/496922
9. Sydnor E. R. M., Perl T. M., Hospital epidemiology and infection control in acute-care settings. Clinical Microbiology Reviews 2011 24 1 141 173 2-s2.0-78751507447 10.1128/CMR.00027-10
10. Pfaller M. A., Diekema D. J., Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. Journal of Clinical Microbiology 2004 42 10 4419 4431 2-s2.0-5444272819 10.1128/JCM.42.10.4419-4431.2004
11. Mikulska M., del Bono V., Ratto S., Viscoli C., Occurrence, presentation and treatment of candidemia. Expert Review of Clinical Immunology 2012 8 755 765
12. MacCallum D. M., Hosting infection: experimental models to assay Candida virulence. International Journal of Microbiology 2012 2012 12 2-s2.0-84855598556 10.1155/2012/363764 363764
13. Pfaller M. A., Diekema D. J., Epidemiology of invasive candidiasis: a persistent public health problem. Clinical Microbiology Reviews 2007 20 1 133 163 2-s2.0-33846466508 10.1128/CMR.00029-06
14. Miceli M. H., Díaz J. A., Lee S. A., Emerging opportunistic yeast infections. The Lancet Infectious Diseases 2011 11 2 142 151 2-s2.0-78751683832 10.1016/S1473-3099(10)70218-8
15. Wisplinghoff H., Bischoff T., Tallent S. M., Seifert H., Wenzel R. P., Edmond M. B., Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clinical Infectious Diseases 2004 39 309 317
16. Cheng M.-F., Yang Y.-L., Yao T.-J., Lin C.-Y., Liu J.-S., Tang R.-B., Yu K.-W., Fan Y.-H., Hsieh K.-S., Ho M., Lo H.-J., Risk factors for fatal candidemia caused by Candida albicans and non-albicans Candida species. BMC Infectious Diseases 2005 5, article 22 2-s2.0-25444434148 10.1186/1471-2334-5-22
17. Morrell M., Fraser V. J., Kollef M. H., Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrobial Agents and Chemotherapy 2005 49 9 3640 3645 2-s2.0-24144483474 10.1128/AAC.49.9.3640- 3645.2005
18. Mathew B. P., Nath M., Recent approaches to antifungal therapy for invasive mycoses. ChemMedChem 2009 4 3 310 323 2-s2.0-62749128097 10.1002/cmdc.200800353
19. Kathiravan M. K., Salake A. B., Chothe A. S., Dudhe P. B., Watode R. P., Mukta M. S., Gadhwe S., The biology and chemistry of antifungal agents: a review. Bioorganic & Medicinal Chemistry 2012 20 5678 5698
20. Denning D. W., Hope W. W., Therapy for fungal diseases: opportunities and priorities. Trends in Microbiology 2010 18 5 195 204 2-s2.0-77952547165 10.1016/j.tim.2010.02.004
21. Hof H., A new, broad-spectrum azole antifungal: posaconazole-mechanisms of action and resistance, spectrum of activity. Mycoses 2006 49 1 2 6 2-s2.0-33748564964 10.1111/j.1439-0507.2006.01295.x
22. Hay R., Katsambas A., Lotti T., Antifungal drugs. European Handbook of Dermatological Treatments 2003 Berlin, Germany Springer 700 710
23. Aparicio J. F., Mendes M. V., Antón N., Recio E., Martín J. F., Polyene macrolide antiobiotic biosynthesis. Current Medicinal Chemistry 2004 11 12 1645 1656 2-s2.0-2942560715
24. Grover N., Echinocandins: a ray of hope in antifungal drug therapy. Indian Journal of Pharmacology 2010 42 1 9 11 2-s2.0-77951692443 10.4103/0253-7613.62396
25. Cappelletty D., Eiselstein-McKitrick K., The echinocandins. Pharmacotherapy 2007 27 3 369 388 2-s2.0-33847327475 10.1592/phco.27.3.369
26. Vazquez J. A., Anidulafungin: a new echinocandin with a novel profile. Clinical Therapeutics 2005 27 6 657 673 2-s2.0-27744463412 10.1016/j.clinthera. 2005.06.010
27. Ostrosky-Zeichner L., Kontoyiannis D., Raffalli J., Mullane K. M., Vazquez J., Anaissie E. J., Lipton J., Jacobs P., van Rensburg J. H. J., Rex J. H., Lau W., Facklam D., Buell D. N., International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. European Journal of Clinical Microbiology and Infectious Diseases 2005 24 10 654 661 2-s2.0-27944466696 10.1007/s10096-005-0024-8
28. de Wet N., Llanos-Cuentas A., Suleiman J., Baraldi E., Krantz E. F., Della Negra M., Diekmann-Berndt H., A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clinical Infectious Diseases 2004 39 6 842 849 2-s2.0-4544236835 10.1086/423377
29. Mora-Duarte J., Betts R., Rotstein C., Lopes Colombo A., Thompson-Moya L., Smietana J., Lupinacci R., Sable C., Kartsonis N., Perfect J., Comparison of caspofungin and amphotericin B for invasive candidiasis. The New England Journal of Medicine 2002 347 25 2020 2029 2-s2.0-0037137576 10.1056/NEJMoa021585
30. Sanglard D., Odds F. C., Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. The Lancet Infectious Diseases 2002 2 2 73 85 2-s2.0-0036488166 10.1016/S1473-3099(02)00181-0
31. Vermes A., Guchelaar H.-J., Dankert J., Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. Journal of Antimicrobial Chemotherapy 2000 46 2 171 179 2-s2.0-0033869563
32. Onishi J., Meinz M., Thompson J., Curotto J., Dreikorn S., Rosenbach M., Douglas C., Abruzzo G., Flattery A., Kong L., Cabello A., Vicente F., Pelaez F., Diez M. T., Martin I., Bills G., Giacobbe R., Dombrowski A., Schwartz R., Morris S., Harris G., Tsipouras A., Wilson K., Kurtz M. B., Discovery of novel antifungal (1,3)- β -D-glucan synthase inhibitors. Antimicrobial Agents and Chemotherapy 2000 44 2 368 377 2-s2.0-0033966183 10.1128/AAC.44.2.368-377.2000
33. Sanglard D., Coste A., Ferrari S., Antifungal drug resistance mechanisms in fungal pathogens from the perspective of transcriptional gene regulation. FEMS Yeast Research 2009 9 7 1029 1050 2-s2.0-70350026151 10.1111/j.1567-1364. 2009.00578.x
34. François I. E. J. A., Aerts A. M., Cammue B. P. A., Thevissen K., Currently used antimycotics: spectrum, mode of action and resistance occurrence. Current Drug Targets 2005 6 8 895 907 2-s2.0-27944469561 10.2174/ 138945005774912744
35. Ashley E. S. D., Lewis R., Lewis J. S., Martin C., Andes D., Pharmacology of systemic antifungal agents. Clinical Infectious Diseases 2006 43 1 S28 S39 2-s2.0-33746084037 10.1086/504492
36. Espinel-Ingroff A., Novel antifungal agents, targets or therapeutic strategies for the treatment of invasive fungal diseases: a review of the literature (2005-2009). Revista Iberoamericana de Micologia 2009 26 1 15 22 2-s2.0-67650723105 10.1016/S1130-1406(09)70004-X
37. Lipp H.-P., Clinical pharmacodynamics and pharmacokinetics of the antifungal extended-spectrum triazole posaconazole: an overview. British Journal of Clinical Pharmacology 2010 70 4 471 480 2-s2.0-77956593204 10.1111/j.1365-2125.2010.03680.x
38. Theuretzbacher U., Ihle F., Derendorf H., Pharmacokinetic/pharmacodynamic profile of voriconazole. Clinical Pharmacokinetics 2006 45 7 649 663 2-s2.0-33745632766 10.2165/00003088-200645070-00002
39. Li Y., Theuretzbacher U., Clancy C. J., Nguyen M. H., Derendorf H., Pharmacokinetic/pharmacodynamic profile of posaconazole. Clinical Pharmacokinetics 2010 49 6 379 396 2-s2.0-77952529779 10.2165/11319340- 000000000-00000
40. Theuretzbacher U., Pharmacokinetics/pharmacodynamics of echinocandins. European Journal of Clinical Microbiology and Infectious Diseases 2004 23 11 805 812 2-s2.0-12744273574 10.1007/s10096-004-1228-z
41. Wagner C., Graninger W., Presterl E., Joukhadar C., The echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications. Pharmacology 2006 78 4 161 177 2-s2.0-33845612618 10.1159/000096348
42. Bekersky I., Fielding R. M., Dressler D. E., Lee J. W., Buell D. N., Walsh T. J., Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans. Antimicrobial Agents and Chemotherapy 2002 46 3 828 833 2-s2.0-0036167883 10.1128/AAC.46.3.828-833.2002
43. Kanafani Z. A., Perfect J. R., Resistance to antifungal agents: mechanisms and clinical impact. Clinical Infectious Diseases 2008 46 1 120 128 2-s2.0-39349086422 10.1086/524071
44. Vandeputte P., Ferrari S., Coste A. T., Antifungal resistance and new strategies to control fungal infections. International Journal of Microbiology 2012 2012 26 2-s2.0-84855683118 10.1155/2012/713687 713687
45. Perlin D. S., Antifungal drug resistance: do molecular methods provide a way forward? Current Opinion in Infectious Diseases 2009 22 6 568 573 2-s2.0-70350536660 10.1097/QCO.0b013e3283321ce5
46. Pemán J., Cantón E., Espinel-Ingroff A., Antifungal drug resistance mechanisms. Expert Review of Anti-Infective Therapy 2009 7 4 453 460 2-s2.0-67650179652 10.1586/ERI.09.18
47. Abad M. J., Ansuategui M., Bermejo P., Active antifungal substances from natural sources. Arkivoc 2007 2007 7 116 145 2-s2.0-33846217873
48. Li Y.-Y., Hu Z.-Y., Lu C.-H., Shen Y.-M., Four new terpenoids from Xylaria sp. 101. Helvetica Chimica Acta 2010 93 4 796 802 2-s2.0-77951615707 10.1002/hlca.200900296
49. Bhadury P., Mohammad B. T., Wright P. C., The current status of natural products from marine fungi and their potential as anti-infective agents. Journal of Industrial Microbiology and Biotechnology 2006 33 5 325 337 2-s2.0-33645131690 10.1007/s10295-005-0070-3
50. Sortino M., Derita M., Svetaz L., Raimondi M., Diliberto M., Petenatti E., Gupta M., Zacchino S., Filho V. C., 6. The role of natural products in discovery of new anti-infective agents with emphasis on antifungal compounds. Plant Bioactives and Drug Discovery: Principles, Practice, and Perspectives 2012 205 239
51. Peláez F., Cabello A., Platas G., Diez M. T., Del Val A. G., Basilio A., Martan I., Vicente F., Bills G. F., Giacobbe R. A., Schwartz R. E., Onishi J. C., Meinz M. S., Abruzzo G. K., Flattery A. M., Kong L., Kurtz M. B., The discovery of enfumafungin, a novel antifungal compound produced by an endophytic Hormonema species biological activity and taxonomy of the producing organisms. Systematic and Applied Microbiology 2000 23 3 333 343 2-s2.0-0033678540
52. Olar R., Badea M., Marinescu D., Chifiriuc C.-M., Bleotu C., Grecu M. N., Iorgulescu E. E., Bucur M., Lazar V., Finaru A., Prospects for new antimicrobials based on N,N-dimethylbiguanide complexes as effective agents on both planktonic and adhered microbial strains. European Journal of Medicinal Chemistry 2010 45 7 2868 2875 2-s2.0-77954348554 10.1016/j.ejmech.2010.03.009
53. Olar R., Badea M., Marinescu D., Chifiriuc M.-C., Bleotu C., Grecu M. N., Iorgulescu E.-E., Lazar V., N, N-dimethylbiguanide complexes displaying low cytotoxicity as potential large spectrum antimicrobial agents. European Journal of Medicinal Chemistry 2010 45 7 3027 3034 2-s2.0-77954349758 10.1016/j.ejmech.2010.03.033
54. Anderson E. B., Long T. E., Imidazole- and imidazolium-containing polymers for biology and material science applications. Polymer 2010 51 12 2447 2454 2-s2.0-77954834658 10.1016/j.polymer.2010.02.006
55. Fang B., Zhou C.-H., Rao X.-C., Synthesis and biological activities of novel amine-derived bis-azoles as potential antibacterial and antifungal agents. European Journal of Medicinal Chemistry 2010 45 9 4388 4398 2-s2.0-77955560154 10.1016/j.ejmech.2010.06.012
56. Brouwer C. P. J. M., Rahman M., Welling M. M., Discovery and development of a synthetic peptide derived from lactoferrin for clinical use. Peptides 2011 32 9 1953 1963 2-s2.0-80052724738 10.1016/j.peptides.2011.07.017
57. Heasley B. H., Pacofsky G. J., Mamai A., Liu H., Nelson K., Coti G., Peel M. R., Balkovec J. M., Greenlee M. L., Liberator P., Meng D., Parker D. L., Wilkening R. R., Apgar J. M., Racine F., Hsu M. J., Giacobbe R. A., Kahn J. N., Synthesis and biological evaluation of antifungal derivatives of enfumafungin as orally bioavailable inhibitors of β -1, 3-glucan synthase. Bioorganic & Medicinal Chemistry Letters 2012 22 6811 6816
58. Melo L. D., Mamizuka E. M., Carmona-Ribeiro A. M., Antimicrobial particles from cationic lipid and polyelectrolytes. Langmuir 2010 26 14 12300 12306 2-s2.0-77956706402 10.1021/la101500s
59. Timofeeva L. M., Kleshcheva N. A., Moroz A. F., Didenko L. V., Secondary and tertiary polydiallylammonium salts: novel polymers with high antimicrobial activity. Biomacromolecules 2009 10 11 2976 2986 2-s2.0-70449494882 10.1021/bm900435v
60. Cakmak I., Ulukanli Z., Tuzcu M., Karabuga S., Genctav K., Synthesis and characterization of novel antimicrobial cationic polyelectrolytes. European Polymer Journal 2004 40 10 2373 2379 2-s2.0-4344592247 10.1016/j.eurpolymj.2004. 06.004
61. Sauvet G., Fortuniak W., Kazmierski K., Chojnowski J., Amphiphilic block and statistical siloxane copolymers with antimicrobial activity. Journal of Polymer Science A 2003 41 19 2939 2948 2-s2.0-0141592409 10.1002/pola.10895
62. Zhu J., Luther P. W., Leng Q., Mixson A. J., Synthetic histidine-rich peptides inhibit Candida species and other fungi in vitro: role of endocytosis and treatment implications. Antimicrobial Agents and Chemotherapy 2006 50 8 2797 2805 2-s2.0-33746917547 10.1128/AAC.00411-06
63. Tam J. P., Lu Y.-A., Yang J.-L., Antimicrobial dendrimeric peptides. European Journal of Biochemistry 2002 269 3 923 932 2-s2.0-0036183822 10.1046/j.0014-2956.2001.02728.x
64. Tew G. N., Clements D., Tang H., Arnt L., Scott R. W., Antimicrobial activity of an abiotic host defense peptide mimic. Biochimica et Biophysica Acta 2006 1758 9 1387 1392 2-s2.0-33748929145 10.1016/j.bbamem.2006.03.001
65. Som A., Choi Y., Tew G. N., Monovalent salt effects on the membrane activity of antimicrobial polymers. Macromolecular Symposia 2009 283-284 1 319 325 2-s2.0-70349434916 10.1002/masy.200950937
66. Palermo E. F., Kuroda K., Chemical structure of cationic groups in amphiphilic polymethacrylates modulates the antimicrobial and hemolytic activities. Biomacromolecules 2009 10 6 1416 1428 2-s2.0-67049095706 10.1021/bm900044x
67. Palermo E. F., Sovadinova I., Kuroda K., Structural determinants of antimicrobial activity and biocompatibility in membrane-disrupting methacrylamide random copolymers. Biomacromolecules 2009 10 11 3098 3107 2-s2.0-70449509374 10.1021/bm900784x
68. Caillier L., Taffin de Givenchy E., Levy R., Vandenberghe Y., Geribaldi S., Guittard F., Polymerizable semi-fluorinated gemini surfactants designed for antimicrobial materials. Journal of Colloid and Interface Science 2009 332 1 201 207 2-s2.0-59049096871 10.1016/j.jcis.2008.12.038
69. Patel M. B., Patel S. A., Ray A., Patel R. M., Synthesis, characterization, and antimicrobial activity of acrylic copolymers. Journal of Applied Polymer Science 2003 89 4 895 900 2-s2.0-0037711362 10.1002/app.11970
70. Patel J. N., Dolia M. B., Patel K. H., Patel R. M., Homopolymer of 4-chloro-3-methyl phenyl methacrylate and its copolymers with butyl methacrylate: synthesis, characterization, reactivity ratios and antimicrobial activity. Journal of Polymer Research 2006 13 3 219 228 2-s2.0-33644959483 10.1007/s10965-005-9029-3
71. Muñoz-Bonilla A., Fernández-García M., Polymeric materials with antimicrobial activity. Progress in Polymer Science 2012 37 281 339
72. Senthil Kumar R., Sasikala K., Arunachalam S., DNA interaction of some polymer-copper(II) complexes containing 2,2′-bipyridyl ligand and their antimicrobial activities. Journal of Inorganic Biochemistry 2008 102 2 234 241 2-s2.0-38149064642 10.1016/j.jinorgbio.2007.08.005
73. Soykan C., Coskun R., Kirbag S., Poly(crotonic acid-co-2-acrylamido-2- methyl-1-propanesulfonic acid)-metal complexes with copper(II), cobalt(II), and nickel(II): synthesis, characterization and antimicrobial activity. European Polymer Journal 2007 43 9 4028 4036 2-s2.0-34548284010 10.1016/j.eurpolymj.2007. 06.033
74. Yue I. C., Poff J., Cortés M. E., Sinisterra R. D., Faris C. B., Hildgen P., Langer R., Shastri V. P., A novel polymeric chlorhexidine delivery device for the treatment of periodontal disease. Biomaterials 2004 25 17 3743 3750 2-s2.0-1542328768 10.1016/j.biomaterials.2003.09.113
75. Kiremitçi A. S., Çiftçi A., Özalp M., Gümüşderelioǧlu M., Novel chlorhexidine releasing system developed from thermosensitive vinyl ether-based hydrogels. Journal of Biomedical Materials Research B 2007 83 609 614
76. Zhang H., Wang D., Butler R., Campbell N. L., Long J., Tan B., Duncalf D. J., Foster A. J., Hopkinson A., Taylor D., Angus D., Cooper A. I., Rannard S. P., Formation and enhanced biocidal activity of water-dispersable organic nanoparticles. Nature Nanotechnology 2008 3 8 506 511 2-s2.0-49449095262 10.1038/nnano.2008.188
77. Kong H., Song J., Jang J., One-step preparation of antimicrobial polyrhodanine nanotubes with silver nanoparticles. Macromolecular Rapid Communications 2009 30 15 1350 1355 2-s2.0-68249104150 10.1002/marc.200900106
78. Kong H., Jang J., Synthesis and antimicrobial properties of novel silver/polyrhodanine nanofibers. Biomacromolecules 2008 9 10 2677 2681 2-s2.0-55049135069 10.1021/bm800574x
79. Duan Y.-Y., Jia J., Wang S.-H., Yan W., Jin L., Wang Z.-Y., Preparation of antimicrobial poly(e-caprolactone) electrospun nanofibers containing silver-loaded zirconium phosphate nanoparticles. Journal of Applied Polymer Science 2007 106 2 1208 1214 2-s2.0-34548536352 10.1002/app.26786
80. Hata K., Horii T., Miyazaki M., Watanabe N.-A., Okubo M., Sonoda J., Nakamoto K., Tanaka K., Shirotori S., Murai N., Inoue S., Matsukura M., Abe S., Yoshimatsu K., Asada M., Efficacy of oral E1210, a new broad-spectrum antifungal with a novel mechanism of action, in murine models of candidiasis, aspergillosis, and fusariosis. Antimicrobial Agents and Chemotherapy 2011 55 10 4543 4551 2-s2.0-80052856780 10.1128/AAC.00366-11
81. Pasqualotto A. C., Denning D. W., New and emerging treatments for fungal infections. The Journal of Antimicrobial Chemotherapy 2008 61 i19 i30 2-s2.0-41949128129 10.1093/jac/dkm428
82. Girmenia C., New generation azole antifungals in clinical investigation. Expert Opinion on Investigational Drugs 2009 18 9 1279 1295 2-s2.0-68849117064 10.1517/13543780903176407
83. Schmitt-Hoffmann A., Roos B., Heep M., Schleimer M., Weidekamm E., Brown T., Roehrle M., Beglinger C., Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in healthy volunteers. Antimicrobial Agents and Chemotherapy 2006 50 1 279 285 2-s2.0-29944441643 10.1128/AAC.50.1.279-285.2006
84. Meis J. F. G. M., Verweij P. E., Current management of fungal infections. Drugs 2001 61 1 13 25 2-s2.0-0035137216
85. Hoffman H. L., Ernst E. J., Klepser M. E., Novel triazole antifungal agents. Expert Opinion on Investigational Drugs 2000 9 3 593 605 2-s2.0-0034001737
86. Livermore D. M., The need for new antibiotics. Clinical Microbiology and Infection 2004 10 4 1 9 2-s2.0-16644364407
87. Redding S. W., Kirkpatrick W. R., Saville S., Coco B. J., White W., Fothergill A., Rinaldi M., Eng T., Patterson T. F., Lopez-Ribot J., Multiple patterns of resistance to fluconazole in Candida glabrata isolates from a patient with oropharyngeal candidiasis receiving head and neck radiation. Journal of Clinical Microbiology 2003 41 2 619 622 2-s2.0-12244280807 10.1128/JCM.41.2.619-622.2003
88. Skiest D. J., Vazquez J. A., Anstead G. M., Graybill J. R., Reynes J., Ward D., Hare R., Boparai N., Isaacs R., Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection. Clinical Infectious Diseases 2007 44 4 607 614 2-s2.0-33846902613 10.1086/511039
89. Ribeiro M., Paula C. R., Perfect J. R., Cox G. M., Phenotypic and genotypic evaluation of fluconazole resistance in vaginal Candida strains isolated from HIV-infected women from Brazil. Medical Mycology 2005 43 7 647 650 2-s2.0-30644464860 10.1080/13693780500093838
90. Vazquez J. A., Peng G., Sabel J. O., Steele-Moore L., Schuman P., Holloway W., Neaton J. D., Evolution of antifungal susceptibility among Candida species isolates recovered from human immunodeficiency virus-infected women receiving fluconazole prophylaxis. Clinical Infectious Diseases 2001 33 7 1069 1075 2-s2.0-0035478409 10.1086/322641
91. Safdar A., van Rhee F., Henslee-Downey J. P., Singhal S., Mehta J., Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome. Bone Marrow Transplantation 2001 28 9 873 878 2-s2.0-0035201070 10.1038/sj.bmt.1703252
92. Cuenca-Estrella M., Gomez-Lopez A., Mellado E., Buitrago M. J., Monzon A., Rodriguez-Tudela J. L., Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi. Antimicrobial Agents and Chemotherapy 2006 50 3 917 921 2-s2.0-33644661057 10.1128/AAC.50.3.917-921.2006
93. Pfaller M. A., Messer S. A., Boyken L., Rice C., Tendolkar S., Hollis R. J., Diekema D. J., Use of fluconazole as a surrogate marker to predict susceptibility and resistance to voriconazole among 13,338 clinical isolates of Candida spp. tested by clinical and laboratory standards institute-recommended broth microdilution methods. Journal of Clinical Microbiology 2007 45 1 70 75 2-s2.0-33846216881 10.1128/JCM.01551-06
94. Pfaller M. A., Messer S. A., Boyken L., Rice C., Tendolkar S., Hollis R. J., Diekema D. J., Cross-resistance between fluconazole and ravuconazole and the use of fluconazole as a surrogate marker to predict susceptibility and resistance to ravuconazole among 12,796 clinical isolates of Candida spp. Journal of Clinical Microbiology 2004 42 7 3137 3141 2-s2.0-3142724766 10.1128/JCM.42.7.3137-3141.2004
95. Noël T., The cellular and molecular defense mechanisms of the Candida yeasts against azole antifungal drugs. Journal de Mycologie Médicale 2012 22 173 178 10.1016/j.mycmed.2012.04.004
96. Cannon R. D., Lamping E., Holmes A. R., Niimi K., Baret P. V., Keniya M. V., Tanabe K., Niimi M., Goffeau A., Monk B. C., Efflux-mediated antifungal drug resistance. Clinical Microbiology Reviews 2009 22 2 291 321 2-s2.0-66449112829 10.1128/CMR.00051-08
97. Coste A. T., Karababa M., Ischer F., Bille J., Sanglard D., TAC1, transcriptional activator of CDR genes, is a new transcription factor involved in the regulation of Candida albicans ABC transporters CDR1 and CDR2. Eukaryotic Cell 2004 3 6 1639 1652 2-s2.0-11144270183 10.1128/EC.3.6.1639-1652.2004
98. Coste A., Turner V., Ischer F., Morschhäuser J., Forche A., Selmecki A., Berman J., Bille J., Sanglard D., A mutation in TAC1p, a transcription factor regulating CDR1 and CDR2, is coupled with loss of heterozygosity at chromosome 5 to mediate antifungal resistance in Candida albicans. Genetics 2006 172 4 2139 2156 2-s2.0-33646171879 10.1534/genetics.105.054767
99. Coste A. T., Crittin J., Bauser C., Rohde B., Sanglard D., Functional analysis of cis-and trans-acting elements of the Candida albicans CDR2 promoter with a novel promoter reporter system. Eukaryotic Cell 2009 8 8 1250 1267 2-s2.0-68549128735 10.1128/EC.00069-09
100. Torelli R., Posteraro B., Ferrari S., La Sorda M., Fadda G., Sanglard D., Sanguinetti M., The ATP-binding cassette transporter-encoding gene CgSNQ2 is contributing to the CgPDR1-dependent azole resistance of Candida glabrata. Molecular Microbiology 2008 68 1 186 201 2-s2.0-40549126935 10.1111/j.1365-2958. 2008.06143.x
101. Sanglard D., Ischer F., Calabrese D., Majcherczyk P. A., Bille J., The ATP binding cassette transporter gene CgCDR1 from Candida glabrata is involved in the resistance of clinical isolates to azole antifungal agents. Antimicrobial Agents and Chemotherapy 1999 43 11 2753 2765 2-s2.0-0032734512
102. Bennett J. E., Izumikawa K., Marr K. A., Mechanism of Increased Fluconazole Resistance in Candida glabrata during Prophylaxis. Antimicrobial Agents and Chemotherapy 2004 48 5 1773 1777 2-s2.0-2142810157 10.1128/AAC.48.5.1773-1777.2004
103. Moran G. P., Sanglard D., Donnelly S. M., Shanley D. B., Sullivan D. J., Coleman D. C., Identification and expression of multidrug transporters responsible for fluconazole resistance in Candida dubliniensis. Antimicrobial Agents and Chemotherapy 1998 42 7 1819 1830 2-s2.0-0031807122
104. Lamping E., Ranchod A., Nakamura K., Tyndall J. D. A., Niimi K., Holmes A. R., Niimi M., Cannon R. D., Abc1p is a multidrug efflux transporter that tips the balance in favor of innate azole resistance in Candida krusei. Antimicrobial Agents and Chemotherapy 2009 53 2 354 369 2-s2.0-59749098790 10.1128/AAC.01095-08
105. Katiyar S. K., Edlind T. D., Identification and expression of multidrug resistance-related ABC transporter genes in Candida krusei. Medical Mycology 2001 39 1 109 116 2-s2.0-0035120054
106. Vermitsky J.-P., Edlind T. D., Azole resistance in Candida glabrata: coordinate upregulation of multidrug transporters and evidence for a Pdr1-like transcription factor. Antimicrobial Agents and Chemotherapy 2004 48 10 3773 3781 2-s2.0-4644254793 10.1128/AAC.48.10.3773-3781.2004
107. Vermitsky J.-P., Earhart K. D., Smith W. L., Homayouni R., Edlind T. D., Rogers P. D., Pdr1 regulates multidrug resistance in Candida glabrata: gene disruption and genome-wide expression studies. Molecular Microbiology 2006 61 3 704 722 2-s2.0-33748042707 10.1111/j.1365-2958.2006.05235.x
108. Tsai H.-F., Krol A. A., Sarti K. E., Bennett J. E., Candida glabrata PDR1, a transcriptional regulator of a pleiotropic drug resistance network, mediates azole resistance in clinical isolates and petite mutants. Antimicrobial Agents and Chemotherapy 2006 50 4 1384 1392 2-s2.0-33645773419 10.1128/AAC.50.4.1384-1392.2006
109. Martel C. M., Parker J. E., Bader O., Weig M., Gross U., Warrilow A. G. S., Rolley N., Kelly D. E., Kelly S. L., Identification and characterization of four azole-resistant erg3 mutants of Candida albicans. Antimicrobial Agents and Chemotherapy 2010 54 11 4527 4533 2-s2.0-78049243452 10.1128/AAC.00348-10
110. Miyazaki Y., Geber A., Miyazaki H., Falconer D., Parkinson T., Hitchcock C., Grimberg B., Nyswaner K., Bennett J. E., Cloning, sequencing, expression and allelic sequence diversity of ERG3 (C-5 sterol desaturase gene) in Candida albicans. Gene 1999 236 1 43 51 2-s2.0-0032783722 10.1016/S0378-1119(99)00263-2
111. Hernandez S., López-Ribot J. L., Najvar L. K., McCarthy D. I., Bocanegra R., Graybill J. R., Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive candida esophagitis. Antimicrobial Agents and Chemotherapy 2004 48 4 1382 1383 2-s2.0-1642420267 10.1128/AAC.48.4.1382-1383.2004
112. Krogh-Madsen M., Arendrup M. C., Heslet L., Knudsen J. D., Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient. Clinical Infectious Diseases 2006 42 7 938 944 2-s2.0-33645081452 10.1086/500939
113. Hakki M., Staab J. F., Marr K. A., Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy. Antimicrobial Agents and Chemotherapy 2006 50 7 2522 2524 2-s2.0-33745629383 10.1128/AAC.00148-06
114. Pasquale T., Tomada J. R., Ghannoun M., Dipersio J., Bonilla H., Emergence of Candida tropicalis resistant to caspofungin. Journal of Antimicrobial Chemotherapy 2008 61 1 219 2-s2.0-37549010995 10.1093/jac/dkm453
115. Alexander B., Johnson M., Pfeiffer C., Jiménez-Ortigosa C., Catania J., Booker R., Castanheira M., Messer S., Perlin D., Pfaller M., Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clinical Infectious Diseases 2013 56 1724 1732 10.1093/cid/cit136
116. Pfaller M. A., Castanheira M., Lockhart S. R., Ahlquist A. M., Messer S. A., Jones R. N., Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata. Journal of Clinical Microbiology 2012 50 4 1199 1203 2-s2.0-84858609691 10.1128/JCM.06112-11
117. Garcia-Effron G., Katiyar S. K., Park S., Edlind T. D., Perlin D. S., A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. Antimicrobial Agents and Chemotherapy 2008 52 7 2305 2312 2-s2.0-46249106060 10.1128/AAC.00262-08
118. Cantón E., Pemán J., Sastre M., Romero M., Espinel-Ingroff A., Killing kinetics of caspofungin, micafungin, and amphotericin B against Candida guilliermondii. Antimicrobial Agents and Chemotherapy 2006 50 8 2829 2832 2-s2.0-33746924090 10.1128/AAC.00524-06
119. Kahn J. N., Garcia-Effron G., Hsu M.-J., Park S., Marr K. A., Perlin D. S., Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase. Antimicrobial Agents and Chemotherapy 2007 51 5 1876 1878 2-s2.0-34248375952 10.1128/AAC.00067-07
120. Park S., Kelly R., Kahn J. N., Robles J., Hsu M.-J., Register E., Li W., Vyas V., Fan H., Abruzzo G., Flattery A., Gill C., Chrebet G., Parent S. A., Kurtz M., Teppler H., Douglas C. M., Perlin D. S., Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrobial Agents and Chemotherapy 2005 49 8 3264 3273 2-s2.0-23044471740 10.1128/AAC.49.8.3264-3273.2005
121. Balashov S. V., Park S., Perlin D. S., Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1. Antimicrobial Agents and Chemotherapy 2006 50 6 2058 2063 2-s2.0-33744504444 10.1128/AAC.01653-05
122. Garcia-Effron G., Park S., Perlin D. S., Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. Antimicrobial Agents and Chemotherapy 2009 53 1 112 122 2-s2.0-59749090444 10.1128/AAC.01162-08
123. Laniado-Laborín R., Cabrales-Vargas M. N., Amphotericin B: side effects and toxicity. Revista Iberoamericana de Micologia 2009 26 4 223 227 2-s2.0-70450277392 10.1016/j.riam.2009.06.003
124. Ellis D., Amphotericin B: spectrum and resistance. Journal of Antimicrobial Chemotherapy 2002 49 supplement 1 7 10 2-s2.0-0036178410
125. Rex J. H., Walsh T. J., Sobel J. D., Filler S. G., Pappas P. G., Dismukes
126. Kontoyiannis D. P., Lewis R. E., Antifungal drug resistance of pathogenic fungi. The Lancet 2002 359 9312 1135 1144 2-s2.0-0037197022 10.1016/S0140-6736(02)08162-X
127. Pappas P. G., Rex J. H., Sobel J. D., Filler S. G., Dismukes W. E., Walsh T. J., Edwards J. E., Guidelines for treatment of Candidiasis. Clinical Infectious Diseases 2004 38 2 161 189 2-s2.0-0742299199 10.1086/380796
128. Espinel-Ingroff A., Mechanisms of resistance to antifungal agents: yeasts and filamentous fungi. Revista Iberoamericana de Micologia 2008 25 2 101 106 2-s2.0-44849143048
129. Vandeputte P., Tronchin G., Bergès T., Hennequin C., Chabasse D., Bouchara J.-P., Reduced susceptibility to polyenes associated with a missense mutation in the ERG6 gene in a clinical isolate of Candida glabrata with pseudohyphal growth. Antimicrobial Agents and Chemotherapy 2007 51 3 982 990 2-s2.0-33847611100 10.1128/AAC.01510-06
130. Kelly S. L., Lamb D. C., Kelly D. E., Manning N. J., Loeffler J., Hebart H., Schumacher U., Einsele H., Resistance to fluconazole and cross-resistance to amphotericin B in Candida albicans from AIDS patients caused by defective sterol Δ5,6-desaturation. FEBS Letters 1997 400 1 80 82 2-s2.0-0031024163 10.1016/S0014-5793(96)01360-9
131. Chapeland-Leclerc F., Bouchoux J., Goumar A., Chastin C., Villard J., Noël T., Inactivation of the FCY2 gene encoding purine-cytosine permease promotes cross-resistance to flucytosine and fluconazole in Candida lusitaniae. Antimicrobial Agents and Chemotherapy 2005 49 8 3101 3108 2-s2.0-23044453091 10.1128/AAC.49.8.3101-3108.2005
132. Vandeputte P., Pineau L., Larcher G., Noel T., Brèthes D., Chabasse D., Bouchara J.-P., Molecular mechanisms of resistance to 5-fluorocytosine in laboratory mutants of Candida glabrata. Mycopathologia 2011 171 1 11 21 2-s2.0-78650511059 10.1007/s11046-010-9342-1
133. Duarte M. C. T., Figueira G. M., Sartoratto A., Rehder V. L. G., Delarmelina C., Anti-Candida activity of Brazilian medicinal plants. Journal of Ethnopharmacology 2005 97 2 305 311 2-s2.0-13544272742 10.1016/j.jep.2004.11.016
134. Butler M. S., The role of natural product chemistry in drug discovery. Journal of Natural Products 2004 67 12 2141 2153 2-s2.0-11344292132 10.1021/np040106y
135. Mondello F., de Bernardis F., Girolamo A., Cassone A., Salvatore G., In vivo activity of terpinen-4-ol, the main bioactive component of Melaleuca alternifolia Cheel (tea tree) oil against azole-susceptible and -resistant human pathogenic Candida species. BMC Infectious Diseases 2006 6, article 158 2-s2.0-33751341585 10.1186/1471-2334-6-158
136. Manohar V., Ingram C., Gray J., Talpur N. A., Echard B. W., Bagchi D., Preuss H. G., Antifungal activities of origanum oil against Candida albicans. Molecular and Cellular Biochemistry 2001 228 1-2 111 117 2-s2.0-0035707457 10.1023/A:1013311632207
137. Dalleau S., Cateau E., Bergès T., Berjeaud J.-M., Imbert C., In vitro activity of terpenes against Candida biofilms. International Journal of Antimicrobial Agents 2008 31 6 572 576 2-s2.0-43549118135 10.1016/j.ijantimicag. 2008.01.028
138. Zore G. B., Thakre A. D., Jadhav S., Karuppayil S. M., Terpenoids inhibit Candida albicans growth by affecting membrane integrity and arrest of cell cycle. Phytomedicine 2011 18 13 1181 1190 2-s2.0-80053917396 10.1016/j.phymed.2011.03.008
139. Gunatilaka A. A. L., Natural products from plant-associated microorganisms: distribution, structural diversity, bioactivity, and implications of their occurrence. Journal of Natural Products 2006 69 3 509 526 2-s2.0-33645978063 10.1021/np058128n
140. Aher N. G., Pore V. S., Mishra N. N., Kumar A., Shukla P. K., Sharma A., Bhat M. K., Synthesis and antifungal activity of 1,2,3-triazole containing fluconazole analogues. Bioorganic and Medicinal Chemistry Letters 2009 19 3 759 763 2-s2.0-58549096268 10.1016/j.bmcl.2008.12.026
141. Kofla G., Ruhnke M., Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis-review of the literature. European Journal of Medical Research 2011 16 4 159 166 2-s2.0-79955920230
142. Fernández A., Soriano E., Hernández-Muñoz P., Gavara R., Migration of antimicrobial silver from composites of polylactide with silver zeolites. Journal of Food Science 2010 75 3 E186 E193 2-s2.0-77953949113 10.1111/j.1750-3841.2010.01549.x
143. Ozay O., Akcali A., Otkun M. T., Silan C., Aktas N., Sahiner N., P(4-VP) based nanoparticles and composites with dual action as antimicrobial materials. Colloids and Surfaces B 2010 79 2 460 466 2-s2.0-77953917375 10.1016/j.colsurfb.2010.05.013
144. Watanabe N.-A., Miyazaki M., Horii T., Sagane K., Tsukahara K., Hata K., E1210, a new broad-spectrum antifungal, suppresses Candida albicans hyphal growth through inhibition of glycosylphosphatidylinositol biosynthesis. Antimicrobial Agents and Chemotherapy 2012 56 2 960 971 2-s2.0-84856073587 10.1128/AAC.00731-11
145. Miyazaki M., Horii T., Hata K., Watanabe N.-A., Nakamoto K., Tanaka K., Shirotori S., Murai N., Inoue S., Matsukura M., Abe S., Yoshimatsu K., Asada M., In vitro activity of E1210, a novel antifungal, against clinically important yeasts and molds. Antimicrobial Agents and Chemotherapy 2011 55 10 4652 4658 2-s2.0-80052854203 10.1128/AAC.00291-11
146. Bartroli J., Merlos M., Overview of albaconazole. European Infectious Disease 2011 5 2 88 91 2-s2.0-84857583704
147. Majithiya J., Sharp A., Parmar A., Denning D. W., Warn P. A., Efficacy of isavuconazole, voriconazole and fluconazole in temporarily neutropenic murine models of disseminated Candida tropicalis and Candida krusei. Journal of Antimicrobial Chemotherapy 2009 63 1 161 166 2-s2.0-57649180452 10.1093/jac/dkn431
148. Odds F. C., Drug evaluation: BAL-8557-a novel broad-spectrum triazole antifungal. Current Opinion in Investigational Drugs 2006 7 8 766 772 2-s2.0-33747584657
149. Livermore J., Hope W., Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections. Expert Opinion on Drug Metabolism & Toxicology 2012 8 759 765 Tecnológica